NO20035301D0 - Små molekyl¶re antagonister av proteiner i BCL-2-familien - Google Patents

Små molekyl¶re antagonister av proteiner i BCL-2-familien

Info

Publication number
NO20035301D0
NO20035301D0 NO20035301A NO20035301A NO20035301D0 NO 20035301 D0 NO20035301 D0 NO 20035301D0 NO 20035301 A NO20035301 A NO 20035301A NO 20035301 A NO20035301 A NO 20035301A NO 20035301 D0 NO20035301 D0 NO 20035301D0
Authority
NO
Norway
Prior art keywords
bcl
proteins
family
small molecular
antagonists
Prior art date
Application number
NO20035301A
Other languages
English (en)
Inventor
Shaomeng Wang
Dajun Yang
Original Assignee
Univ Georgetown Med Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown Med Center filed Critical Univ Georgetown Med Center
Publication of NO20035301D0 publication Critical patent/NO20035301D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20035301A 2001-05-30 2003-11-28 Små molekyl¶re antagonister av proteiner i BCL-2-familien NO20035301D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29398301P 2001-05-30 2001-05-30
PCT/US2002/017206 WO2002097053A2 (en) 2001-05-30 2002-05-30 Small molecule antagonists of bcl2 family proteins
US10/158,769 US20030008924A1 (en) 2001-05-30 2002-05-30 Small molecule antagonists of Bcl-2 family proteins

Publications (1)

Publication Number Publication Date
NO20035301D0 true NO20035301D0 (no) 2003-11-28

Family

ID=31495521

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035301A NO20035301D0 (no) 2001-05-30 2003-11-28 Små molekyl¶re antagonister av proteiner i BCL-2-familien

Country Status (18)

Country Link
US (1) US20030008924A1 (no)
EP (1) EP1474121B1 (no)
JP (1) JP2005515158A (no)
KR (1) KR20040108528A (no)
CN (1) CN1589135A (no)
AT (1) ATE474568T1 (no)
AU (1) AU2002305769B2 (no)
CA (1) CA2449245A1 (no)
DE (1) DE60237115D1 (no)
ES (1) ES2349349T3 (no)
HK (1) HK1071066A1 (no)
IL (1) IL159110A0 (no)
MX (1) MXPA03010977A (no)
NO (1) NO20035301D0 (no)
NZ (1) NZ529792A (no)
SG (1) SG157952A1 (no)
WO (1) WO2002097053A2 (no)
ZA (1) ZA200309306B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20023357D0 (no) * 2002-04-19 2002-07-11 Amersham Health As Blanding
US20070060615A1 (en) * 2003-02-18 2007-03-15 University Of South Florida Method of Modulating Apoptosis Through Modulation of E2F1
WO2005009434A2 (en) * 2003-06-25 2005-02-03 The Burnham Institute Compounds and methods for inducing apoptosis in cancer cells
CA2561303C (en) * 2004-03-25 2011-01-18 The Regents Of The University Of Michigan Gossypol co-crystals and the use thereof
AU2005265131B2 (en) 2004-06-17 2012-02-23 Infinity Discovery, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
WO2006099193A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法
EP2007706A2 (en) * 2006-03-30 2008-12-31 The Regents of the University of Michigan Production of gossypol co-crystals
US20100137239A1 (en) 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
TWI389895B (zh) 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
US7857804B2 (en) 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
US20090030088A1 (en) * 2007-04-20 2009-01-29 Clemson University Therapeutic benefits of gossypol, 6-methoxy gossypol, and 6,6'-dimothxy gossypol
WO2009036035A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
WO2009052443A1 (en) * 2007-10-19 2009-04-23 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
US20110144125A1 (en) * 2008-08-14 2011-06-16 The Uab Research Foundation Anti-Arrhythmia Agents, Methods of Their Use, Methods of Their Identification and Kits Therefore
EP2367425B1 (en) * 2008-12-11 2018-02-28 Abraxis BioScience, LLC Combination therapy including a taxane and a further therapeutic agent
CN102548945A (zh) * 2009-10-08 2012-07-04 桑福德-伯纳姆医学研究院 作为抗癌剂的阿朴棉子酚酮衍生物
US20120190817A2 (en) 2010-07-12 2012-07-26 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US8940737B2 (en) * 2011-10-14 2015-01-27 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
JP2015503516A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
WO2013096060A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
CN104125954A (zh) 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
KR20140107575A (ko) 2011-12-23 2014-09-04 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
WO2015123617A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for reducing bcl2 gene expression
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
CA2955972A1 (en) 2014-07-22 2016-01-28 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
CN105884634B (zh) * 2015-01-05 2019-06-04 南开大学 棉酚衍生物和它们的制备,在农药上的应用及抗癌活性
CA2990477A1 (en) 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
WO2017087810A1 (en) * 2015-11-20 2017-05-26 Memorial Sloan-Kettering Cancer Center Method for screening inhibitors targeting anti-apoptotic survival pathways
WO2017142348A1 (ko) * 2016-02-18 2017-08-24 연세대학교 산학협력단 폴리페놀 화합물을 유효성분으로 포함하는 암 치료용 약학조성물
JP6829723B2 (ja) 2016-02-18 2021-02-10 インダストリー−アカデミック コオペレイション ファウンデーション、ヨンセイ ユニバーシティ ポリフェノール化合物を有効成分として含む癌治療用薬学組成物
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN109718377B (zh) * 2017-10-31 2021-03-26 中国科学院脑科学与智能技术卓越创新中心 KPNB1抑制剂和Bcl-xL抑制剂在制备抗肿瘤药物中的应用
CN112105360B (zh) 2018-01-22 2024-01-30 生物风险投资有限责任公司 用于癌症治疗的bcl-2蛋白降解剂
CN109876145A (zh) * 2019-04-25 2019-06-14 中国科学院化学研究所 醋酸棉酚和化疗药的联合用药物
CA3142361A1 (en) 2019-06-12 2020-12-17 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
WO2023107606A1 (en) 2021-12-09 2023-06-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders for treatment of cancers
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806568A (en) * 1985-09-12 1989-02-21 Research Corporation Gossypol derivatives
US5026726A (en) * 1989-12-11 1991-06-25 The University Of New Mexico Gossylic iminolactones and gossylic lactones and their anti-viral activities
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method

Also Published As

Publication number Publication date
CA2449245A1 (en) 2002-12-05
DE60237115D1 (de) 2010-09-02
EP1474121A2 (en) 2004-11-10
EP1474121A4 (en) 2006-05-03
ZA200309306B (no) 2006-07-26
MXPA03010977A (es) 2005-04-08
US20030008924A1 (en) 2003-01-09
CN1589135A (zh) 2005-03-02
HK1071066A1 (en) 2005-07-08
ES2349349T3 (es) 2010-12-30
SG157952A1 (en) 2010-01-29
EP1474121B1 (en) 2010-07-21
KR20040108528A (ko) 2004-12-24
AU2002305769B2 (en) 2007-07-19
WO2002097053A2 (en) 2002-12-05
JP2005515158A (ja) 2005-05-26
WO2002097053A3 (en) 2004-09-10
NZ529792A (en) 2007-04-27
IL159110A0 (en) 2004-06-01
ATE474568T1 (de) 2010-08-15

Similar Documents

Publication Publication Date Title
NO20035301D0 (no) Små molekyl¶re antagonister av proteiner i BCL-2-familien
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
PT1117440E (pt) Composicoes farmaceuticas que contem paclitaxel
MEP8209A (en) Modified factor viii
DE60045394D1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
PH12013500123A1 (en) Hemiasterlin derivatives and uses thereof
NO20062699L (no) Smelteblandingsdispergeringer
DE502005009908D1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
DK1107996T3 (da) Humane anti-faktor IX/IXa-antistoffer
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
MEP20908A (en) Thienopyrazoles
DE60211132D1 (de) 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
ATE355104T1 (de) Haarbehandlungsmittel
PT1282418E (pt) Utilizacao de derivados pirazolo para o tratamento da infertilidade
ATE326985T1 (de) Lyophilisierte pharmazeutische zusammensetzung von propofol
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
EA200600992A1 (ru) Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение
EA200501301A1 (ru) Ментоловые растворы лекарственных препаратов
WO2004081033A3 (en) Synthesis of proteins by cell-free protein expression
SE0300457D0 (sv) Novel compounds
DE60312684D1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
ATE391489T1 (de) Haarbehandlungszusammensetzungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application